Company intelligence / Profile preview

Nemaura Medical

Loughborough, Leicestershire, United Kingdomnemauramedical.com ↗

Ownership: Public · NMRD
Development stage: Commercial

Overview

Nemaura’s lead product sugarBEAT® has CE Mark approval as a non-invasive continuous glucose monitor. Clinical trials in Europe demonstrated positive results with both Type 1 and Type 2 diabetes patients. The company has also launched Miboko—a digital metabolic health program using its sensor—and continues to develop additional wearable diagnostic devices targeting lactate and body temperature

Therapeutic areas: Women's HealthEndocrinologyInfectious DiseasesMetabolic Disorders
Modalities: DeviceDigital health program
Industry: Physiological Monitoring

Partnerships

Dallas Burston Pharma (Jersey) Ltd – marketing rights agreement for SugarBEAT in UK/Ireland

Financials

Market cap: $4K
Total revenue: $0
Enterprise value: $19.5M

Beyond the preview

Go deeper on Nemaura Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nemaura Medical.

Explore the full profile